New drug PQ203 enters human testing for Hard-to-Treat cancers

NCT ID NCT07190469

Recruiting now Disease control Sponsor: ProteinQure Inc. Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This early-stage trial tests the safety and best dose of a new drug called PQ203 in people with advanced solid tumors, including triple-negative breast cancer. About 80 participants whose cancer has progressed after standard treatments will receive the drug. The goal is to find a safe dose for future studies and see if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 0C6, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS CANCER ADVANCED SOLID TUMORS CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)